Core Insights - Polyrizon Ltd. has signed an agreement with a leading global preclinical Contract Research Organization (CRO) to advance its clinical development program for intranasal solutions [1][2] Group 1: Agreement and Development Program - The agreement is part of Polyrizon's efforts to enhance its clinical development, which includes GMP production of clinical trial material and a successful FDA pre-submission meeting [2][5] - The CRO will conduct preclinical biocompatibility studies in accordance with ISO 10993 standards and GLP requirements, expected to start in Q2 2026 [3][4] - These studies are crucial for supporting regulatory submissions and ensuring product safety before human trials [4][5] Group 2: Technology and Product Overview - Polyrizon specializes in developing innovative medical device hydrogels delivered as nasal sprays, which create a barrier against viruses and allergens [6] - The proprietary Capture and Contain TM hydrogel technology aims to function as a "biological mask" in the nasal cavity [6] - The company is also developing the Trap and Target ™ technology for nasal delivery of active pharmaceutical ingredients, which is in earlier preclinical stages [6]